AUSAF (Australis Capital) Forward PE Ratio: 0.00 (As of Jul. 12, 2026)


What is Australis Capital Forward PE Ratio?

Australis Capital AUSAF Forward PE Ratio is 0.00 as of Jul. 12, 2026.

Australis Capital's Forward PE Ratio for today is 0.00.

Australis Capital's PE Ratio without NRI for today is 0.00.

Australis Capital's PE Ratio (TTM) for today is 0.00.

Australis Capital  (OTCPK:AUSAF) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Australis Capital Forward PE Ratio Related Terms

Australis Capital Forward PE Ratio Historical Data

* Premium members only.

The historical data trend for Australis Capital's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Australis Capital Forward PE Ratio Chart

Australis Capital Annual Data
Trend
Forward PE Ratio

Australis Capital Quarterly Data
Forward PE Ratio

AUSAF vs ZTS, CTLT, VTRS: Forward PE Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Australis Capital's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Australis Capital Forward PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Australis Capital's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Australis Capital's Forward PE Ratio falls into.


Australis Capital Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Frequently Asked Questions Learn more about Forward PE Ratio →
What does a Forward PE Ratio of 0.00 mean?
Australis Capital (AUSAF) has a Forward PE Ratio of 0.00 as of Jul. 12, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Australis Capital and its competitors.
Is Australis Capital's Forward PE Ratio too high?
Australis Capital's current Forward PE Ratio is 0.00.
How does Australis Capital's Forward PE Ratio compare to ZTS and CTLT?
Australis Capital's Forward PE Ratio of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median Forward PE Ratio is 17.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 17.23, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Australis Capital and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 17.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Australis Capital's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australis Capital stock overvalued right now?
Australis Capital (AUSAF) has a current Forward PE Ratio of 0.00. The current Forward PE Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Australis Capital (AUSAF), the current Forward PE Ratio is 0.00 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Australis Capital Business Description

Address 376 E. Warm Springs Road, Suite 190, Las Vegas, NV, USA, 89119
Australis Capital Inc operates as a multi-state operator in the cannabis industry in the US. The company is focused on brands and attractive cannabis licenses in states with favorable economics. AUSA is building an MSO based on a unique and very difficult to imitate strategy. Secure access to low-cost but high-quality biomass enables the company to fuel the expansion of its footprint across the US. The company has a rapidly growing footprint in the U.S. in states, such as California, Nevada, Massachusetts, Missouri, Oklahoma, as well as international operations through its subsidiary ALPS, with projects in Europe, Asia and North America.